BCWorld Pharm Turns Profitable in Q1 2026 Despite High Net Debt Ratio of 114.6%
Q1 2026 consolidated revenue of 19.8 billion KRW, operating profit of 1.8 billion KRW, net profit of 0.79 billion KRW, turning profitable (vs. full-year 2025 net loss of 3.14 billion KRW).
Consolidated net debt of 82.9 billion KRW; net debt-to-equity ratio of 114.6%, indicating continued high financial leverage.
Basic EPS of 33 KRW, turning positive vs. -201 KRW in Q1 2025.
R&D expenditure of 2.0 billion KRW (10.1% of revenue); pipeline includes new drugs and AI-based drug discovery collaboration.
New contracts: exclusive domestic rights for Qutenza (non-opioid pain patch), joint development of Niacin injection, and AI drug discovery partnership.
One pending lawsuit as plaintiff worth 305 million KRW; outcome not predictable.
Approved stock dividend of 92,942 shares (approx. 0.93 billion KRW) and cash dividend of 100 KRW per share for fiscal year 2025; no dividend for Q1 2026.
Retained 5th certification as Innovative Pharmaceutical Company (2024-2027) and holds 29 patents (12 domestic, 17 overseas).